1. Home
  2. ACOG
  3. ACOG News

Latest Alpha Cognition Inc. Common Stock (ACOG) News on October 9, 2025

Alpha Cognition to Present Clinical Data at ASCP Annual Meeting
ACOG

Business Wire

3 days ago

Alpha Cognition to Present Clinical Data at ASCP Annual Meeting

Insiders Rewarded With US$150k Addition To Investment As Alpha Cognition Stock Hits US$144m
ACOG

Simply Wall St.

a month ago

Insiders Rewarded With US$150k Addition To Investment As Alpha Cognition Stock Hits US$144m

Should You Buy Alpha Cognition Inc. (ACOG) After Golden Cross?
ACOG

Zacks

4 months ago

Should You Buy Alpha Cognition Inc. (ACOG) After Golden Cross?

Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory
ACOG

Insider Monkey

4 months ago

Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025
ACOG

Newsfile

5 months ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025

We Think Alpha Cognition (NASDAQ:ACOG) Can Easily Afford To Drive Business Growth
ACOG

Simply Wall St.

5 months ago

We Think Alpha Cognition (NASDAQ:ACOG) Can Easily Afford To Drive Business Growth

Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates
ACOG

Zacks

5 months ago

Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates

Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview
ACOG

Business Wire

5 months ago

Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview

Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview
ACOG

Business Wire

5 months ago

Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

ACOG

Newsfile

5 months ago

Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference
ACOG

Business Wire

5 months ago

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens
ACOG

Business Wire

6 months ago

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024
ACOG

Newsfile

6 months ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024

Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
ACOG

Business Wire

6 months ago

Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
ACOG

Business Wire

7 months ago

Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

ACOG

MT Newswires

7 months ago

Alpha Cognition Launches Zunveyl for Treating Alzheimer's Disease; Shares Up Pre-Bell

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease
ACOG

Business Wire

7 months ago

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease

Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory
ACOG

Insider Monkey

7 months ago

Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory

Alpha Cognition Inc. (NASDAQ:ACOG) surges 13%; retail investors who own 46% shares profited along with institutions
ACOG

Simply Wall St.

8 months ago

Alpha Cognition Inc. (NASDAQ:ACOG) surges 13%; retail investors who own 46% shares profited along with institutions

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease
ACOG

Business Wire

8 months ago

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease

Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)
ACOG

Newsfile

8 months ago

Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)

OTC Markets Group Announces Quarterly Index Performance and Rebalancing
ACOG

GlobeNewswire

9 months ago

OTC Markets Group Announces Quarterly Index Performance and Rebalancing

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
ACOG

Business Wire

9 months ago

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China
ACOG

Business Wire

9 months ago

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call
ACOG

Business Wire

9 months ago

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call

Alpha Cognition Announces Partial Exercise of Over-allotment Option
ACOG

Business Wire

10 months ago

Alpha Cognition Announces Partial Exercise of Over-allotment Option

Alpha Cognition Announces Voluntary Delisting from CSE
ACOG

Business Wire

10 months ago

Alpha Cognition Announces Voluntary Delisting from CSE

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
ACOG

Business Wire

10 months ago

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Share on Social Networks: